Merus NV (MRUS)

Currency in USD
90.00
0.00(0.00%)
Closed·
Showing Merus historical data. For real-time data please try another search
Fair Value
Day's Range
87.1496.86
52 wk Range
33.1997.14
Key Statistics
Prev. Close
90
Open
96.86
Day's Range
87.14-96.86
52 wk Range
33.19-97.14
Volume
2.73M
Average Volume (3m)
1.61M
1-Year Change
108.5264%
Book Value / Share
10.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRUS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
97.00
Upside
+7.78%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Merus NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Merus NV Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

Merus NV SWOT Analysis


Promising Pipeline
Explore Merus N.V.'s innovative multispecific antibody platform, with lead candidate petosemtamab showing strong potential in HNSCC and CRC treatments
Clinical Milestones
Delve into petosemtamab's impressive Phase 2 results, including a 63% ORR in combination therapy and promising monotherapy outcomes in HNSCC
Market Potential
Analysts project U.S. peak sales of $3 billion for petosemtamab in HNSCC alone, with additional upside from potential colorectal cancer indications
Financial Outlook
Despite current losses, Merus maintains a strong cash position. Analyst price targets range from $67 to $109, with profitability expected by 2027
Read full SWOT analysis

Compare MRUS to Peers and Sector

Metrics to compare
MRUS
Peers
Sector
Relationship
P/E Ratio
−17.9x−1.8x−0.6x
PEG Ratio
0.51−0.080.00
Price/Book
8.8x2.9x2.6x
Price / LTM Sales
120.6x6.7x3.3x
Upside (Analyst Target)
7.8%733.3%45.1%
Fair Value Upside
Unlock13.8%5.5%Unlock

Analyst Ratings

1 Buy
9 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 97.00
(+7.78% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Oct 30, 2025
EPS / Forecast
-1.26 / -1.38
Revenue / Forecast
12.15M / 8.59M
EPS Revisions
Last 90 days

MRUS Income Statement

People Also Watch

72.24
BFAM
+0.84%
90.68
KYMR
-0.36%
7.89
KDK
-0.19%
56.920
LDOF
-3.79%
272.50
KRYS
+2.10%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.